H. pylori and gastritis are not two separate problems
In India's gut health data, they appear together so consistently that treating them as separate conditions misses the point. In TumGard's endoscopy cohort of 1,111 adults with persistent gut symptoms, 62% had H. pylori and 24% had confirmed gastritis. These findings are not coincidental — they substantially overlap. In most cases of chronic gastritis in Indian adults, H. pylori is the engine driving the inflammation.
Understanding the mechanism matters because it explains a question many patients have: why doesn't the PPI fix it? The answer is visible in the biology below. Acid suppression doesn't touch any of the six steps in H. pylori's inflammatory pathway.
The six-step inflammatory cascade
This is how H. pylori turns a bacterial infection into chronic, structural mucosal inflammation — step by step.
H. pylori enters the stomach and faces an immediate problem: pH 1–2 acid that would kill most bacteria within seconds. It solves this by producing urease — an enzyme that breaks down urea into ammonia. The ammonia neutralises acid in a small zone around the bacteria, creating a protected microenvironment in which it can survive and multiply indefinitely.
Intervention point: Urease enzymeH. pylori then burrows through the mucus layer and adheres directly to the surface epithelial cells of the gastric antrum. It uses specialised adhesin proteins (BabA, SabA) to bind to specific receptors on goblet cells. This adhesion is what makes H. pylori so difficult to dislodge — it is physically anchored to the tissue, not just floating in gastric fluid.
Intervention point: Mucosal adhesionThe most virulent strains of H. pylori carry the cag pathogenicity island (cag-PAI) — a molecular syringe that injects a toxin called CagA directly into the epithelial cell it's attached to. Once inside, CagA activates multiple cell-signalling pathways and directly activates the NF-kB inflammatory pathway.[1]
Intervention point: CagA / cag-PAINF-kB (nuclear factor kappa B) is the master switch of the inflammatory response — a transcription factor that sits dormant in cells until triggered, then moves to the cell nucleus and switches on the genes for inflammatory cytokines. H. pylori activates NF-kB through multiple routes: CagA injection, outer membrane proteins, and peptidoglycan fragments. Once activated, NF-kB drives continuous inflammation regardless of acid levels.[3]
Intervention point: NF-kB signallingNF-kB activation triggers production of interleukin-8 (IL-8) — a pro-inflammatory cytokine that acts as a recruitment signal for neutrophils and other immune cells. These immune cells flood the gastric mucosa and begin their own inflammatory activity, releasing reactive oxygen species and proteases that cause direct tissue damage. This is what gastritis looks like on endoscopy — mucosal redness, swelling, and erosion driven by immune cell activity.[2]
Intervention point: IL-8 / cytokine loadWith H. pylori present and NF-kB continuously activated, the inflammatory cascade becomes self-sustaining. Goblet cells are damaged faster than they can be replaced. The mucus layer thins. The epithelial surface becomes increasingly vulnerable to acid. Cell turnover is disrupted by the same cytokines driving the damage. Without removing H. pylori, this process continues indefinitely.
Result: Chronic gastritisA proton pump inhibitor blocks the gastric acid pump. Not a single step in the six-stage H. pylori cascade above involves acid production. H. pylori survives whether acid is suppressed or not. NF-kB activates whether acid is present or not. The inflammation continues. The lining continues to degrade. The symptoms return the moment the PPI is stopped.
Why the immune system can't clear it
A reasonable question: if the immune system can fight bacterial infections, why doesn't it clear H. pylori on its own? H. pylori has evolved over millennia specifically to evade immune clearance in the stomach.
It sits inside the mucus layer — not in the bloodstream where antibodies are effective. It modulates regulatory T-cell activity to dampen the immune response. It continuously changes its surface antigens to avoid recognition. The result is a permanent standoff: the immune system mounts continuous low-grade inflammation, H. pylori persists anyway, and the collateral damage to the stomach lining accumulates year after year.
H. pylori is the most common chronic bacterial infection in humans worldwide, and in India it is the primary driver of chronic active gastritis in symptomatic adults. The bacteria evades immune clearance and sustains mucosal inflammation indefinitely — making it a structural rather than episodic problem.
What can actually interrupt the cascade
Understanding the cascade clarifies what effective intervention needs to target. There are three points of leverage:
- Urease inhibition (Step 1). If urease is inhibited, H. pylori's acid-survival mechanism fails. Quercetin and myricetin — flavonoids found in plants — have documented urease inhibitory activity, reducing the bacteria's ability to maintain its protective ammonia shield.
- Anti-adhesion (Step 2). Glabridin, a licorice-derived flavonoid, has been shown to reduce H. pylori's adhesion to gastric epithelial cells — making it easier to dislodge and reducing the intensity of the downstream cascade.
- NF-kB inhibition (Step 4). Quercetin inhibits NF-kB activation, reducing the transcription of pro-inflammatory cytokines. This dampens the IL-8 cascade (Step 5) and reduces the ongoing immune cell infiltration causing mucosal damage.[3]
TumGard's formulation — 700mg of flavonoids per serving, combining quercetin, myricetin, and licorice-derived glabridin — is built around these three intervention points. For the mechanism of mucosal repair after H. pylori is addressed, see: How the Stomach Lining Repairs Itself — The EGFR/ERK Pathway, Explained.
References
- Crowe SE. Helicobacter pylori infection. New England Journal of Medicine. 2019;380(12):1158–1165. PMID 30699316. Authoritative clinical review of H. pylori pathogenesis including CagA toxin mechanism, cag-PAI function, and the link between chronic infection and gastric mucosal inflammation — primary reference for Steps 1–4 in this article.
- Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defence and cytoprotection: bench to bedside. Gastroenterology. 2008;135(1):41–60. PMID 18424695. Documents the mucosal defence cascade and how immune cell infiltration (Step 5) produces the structural mucosal destruction described in Step 6.
- Ye YN, Liu ES, Shin VY, Wu WK, Cho CH. Modulating role of nuclear factor-κB in the gastroprotective action of flavonoids. Journal of Ethnopharmacology. 2023. PMID 36842733. Documents NF-kB inhibition by quercetin in the context of H. pylori-driven gastric inflammation — the mechanistic basis for flavonoid intervention at Step 4 of the cascade.
- Merlin Annie Raj, RD. TumGard India Gut Health Report 2026. Hugg Beverages Pvt. Ltd. 2026. tumgard.com/india-gut-health-report-2026. Source of the 62% H. pylori prevalence and 24% gastritis confirmation rate in the endoscopy sub-cohort (n=1,111) — the Indian data contextualising the mechanism described in this article.
The 62% H. pylori positivity rate in TumGard's endoscopy cohort is consistent with Indian clinical literature, which reports H. pylori prevalence of 50–70% in symptomatic adults undergoing endoscopy (Crowe, NEJM 2019). The mechanistic pathway described (urease → adhesion → CagA → NF-kB → IL-8 → mucosal destruction) is the established consensus model in gastroenterology literature.